CD274 and neoplasm: Pembrolizumab, a highly selective, humanized monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with its ligands, PD-L1 and programmed death ligand 2, has demonstrated activity as monotherapy in numerous tumor types and hematologic malignancies.